The French compassionate programme of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant
Pierre-Régis Burgel, Isabelle Sermet-Gaudelus, Isabelle Durieu, Reem Kanaan, Julie Macey, Dominique Grenet, Michele Porzio, Nathalie Coolen-Allou, Raphael Chiron, Christophe Marguet, Benoit Douvry, Nadine Dufeu, Isabelle Danner-Boucher, Pierre Foucaud, Lydie Lemonnier, Emmanuelle Girodon, Jennifer Da Silva, Clémence Martin
Source: Eur Respir J, 61 (5) 2202437; 10.1183/13993003.02437-2022
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Pierre-Régis Burgel, Isabelle Sermet-Gaudelus, Isabelle Durieu, Reem Kanaan, Julie Macey, Dominique Grenet, Michele Porzio, Nathalie Coolen-Allou, Raphael Chiron, Christophe Marguet, Benoit Douvry, Nadine Dufeu, Isabelle Danner-Boucher, Pierre Foucaud, Lydie Lemonnier, Emmanuelle Girodon, Jennifer Da Silva, Clémence Martin. The French compassionate programme of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant. Eur Respir J, 61 (5) 2202437; 10.1183/13993003.02437-2022
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
|
|